CLAIMS

What is claimed is:

1. A method of preparing a cell suspension suitable for administration to a subject, the method comprising:

(a) thawing a cell suspension, the cell suspension comprising:

a plurality of neural cells; and

one or more cryoprotectants; and

(b) loading the cell suspension into a dose delivery device,

wherein the method does not comprise washing or diluting the cell suspension between step (a) and step (b).

2. The method of claim 1, wherein the cell suspension comprises about 1% to about 30% of one or more cryoprotectants; or wherein the cell suspension comprises about 10% to about 12.5% of one or more cryoprotectants.

3. The method of claim 1, wherein the one or more cryoprotectants comprises DMSO or propylene glycol.

4. The method of claim 1, wherein the dose delivery device comprises a syringe.

5. The method of claim 1, wherein the neural cells comprise midbrain dopaminergic neuronal precursor cells.

6. The method of claim 1, wherein the cell suspension further comprises about 25 mM to about 280 mM of one or more energy source components.

7. The method of claim 6, wherein the one or more energy source components comprise dextrose or glucose.

8. The method of claim 1, wherein the cell suspension further comprises about 10 mM to about 200 mM of one or more salts.

9. The method of claim 8, wherein the one or more salts comprise one or more of calcium chloride, magnesium chloride, potassium chloride, sodium chloride, or sodium phosphate.

10. The method of claim 1, wherein the cell suspension does not include any components of animal origin and wherein the cell suspension does not include sodium pyruvate.

11. The method of claim 1, wherein the cell suspension further comprises:

about 145 mM to about 165 mM glucose;
about 10 mM to about 15 mM HEPES;
about 0.1 mM to about 2.5 mM calcium chloride;
about 0.5 mM to about 1.0 mM magnesium chloride;
about 4.0 mM to about 6.0 mM potassium chloride;
about 60 mM to about 80 mM sodium chloride;
about 0.1% wt to about 10% wt Dextran; and
about 10% wt to about 15% wt of one or more cryoprotectants.

12. The method of claim 1, wherein the cell suspension comprises a therapeutically effective dose of said neural cells, and wherein the therapeutically effective dose comprises at least 2.7 million cells.